30
CARDIOVASCULAR
hamburger

The Amplatzer portfolio of structural intervention occluders provides minimally invasive treatment options for the closure of congenital heart defects and for stroke risk reduction. The closure procedures are performed through a transcatheter approach, which prevents the need for open heart surgery and enables faster recovery times.

 

Structural Interventions: Congenital Heart Defects

Amplatzer™ Duct Occluders

The Amplatzer Family of Duct Occluders offers an extensive line of devices and a simple treatment option for the closure of patent ductus arteriosus (PDA). Amplatzer™ Duct Occluders are designed to occlude PDAs of various shapes and sizes. With an easy-to-perform deployment procedure, the implanting physician can be confident in placing the device with precision.

Amplatzer™ Septal Occluders

Amplatzer™ Septal Occluders are the standard of care for minimally invasive atrial septal defects (ASD) closure.1,2 These double-disc occluders are comprised of nitinol mesh and polyester material. They are designed to securely appose the septal wall on each side of the defect and create a platform for tissue in-growth after implantation.

Amplatzer VSD Occluders

Ventricular septal defects (VSD) are the most commonly found congenital heart defect.3 There are four types of VSDs: muscular, perimembranous, conal or subpulmonary, and inlet. Abbott offers Amplatzer Muscular and Membranous VSD Occluders for complete closure of muscular and perimembranous VSDs.

 

Structural Interventions: Stroke Risk Reduction

Amplatzer™ Amulet™ Left Atrial Appendage Occluder

The Amplatzer™ Amulet™ Left Atrial Appendage (LAA) Occluder is designed for complete occlusion of the LAA, thereby reducing the risk of ischemic stroke in nonvalvular atrial fibrillation patients.

Amplatzer™ PFO Occluder

The Amplatzer™ PFO Occluder set the standard, pioneering treatment with a device developed specifically for patent foramen ovale (PFO) closure to reduce the risk of recurrent ischemic stroke. It’s the leading PFO closure device to date, with over 130,000 devices implanted worldwide.4

  • Manuals & Technical Resources
  • Cardiovascular Products
  • Customer Service

References

  1. Kashour TS, Latroche B, Elhoury ME, et al. Successful percutaneous closure of a secundum atrial septal defect through femoral approach in a patient with interrupted inferior vena cava. Congenit Heart Dis. 2010;5:620–623.
  2. Tadros VX, Asgar AW. Transcatheter closure of atrial septal defects: an update on ASD occlusion devices. Card Interv Today. 2016; March-April.
  3. Hoffman J, Kaplan S. The incidence of congential heart disease. J Am Coll Cardiol. 2002;39(12):1890-1900.
  4. Data on file at Abbott.

MAT-2008012 v1.0 | Item approved for Global OUS use only.

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.